Tirzepatide is linked to lower risk of major heart events
After balancing the groups’ measured characteristics, estimated one-year risks were 2.9% with tirzepatide versus 4.4% with sitagliptin for heart attack, stroke or death.
Registered NCT07203677
Edited by Boris Djordjevic · AgingResearch.News
Researchers conducted an observational cohort study of 52,971 people aged 40 or older with type 2 diabetes and established atherosclerotic cardiovascular disease, which involves plaque buildup in arteries. Using two national US insurance claims databases, they compared 35,353 people starting tirzepatide with 17,618 starting sitagliptin, a diabetes drug considered neutral for cardiovascular outcomes. Follow-up lasted up to one year.
After statistically balancing measured characteristics, estimated one-year risks of heart attack, stroke or death from any cause were 2.9% with tirzepatide and 4.4% with sitagliptin. Tirzepatide was associated with a lower hazard of heart attack and death, but stroke caused by a blocked blood vessel showed no meaningful difference. For infections requiring hospitalization and infection-related death, hazard ratios were 0.64 and 0.40, respectively, compared with sitagliptin. These ratios compare event rates over time; values below one favor tirzepatide.
Why it matters
Cardiovascular disease is a major concern in aging. The authors suggest that mechanisms beyond plaque buildup in arteries may contribute to the observed benefit.
Caveats
Because this was an observational cohort study of insurance claims rather than a randomized trial, unmeasured factors may have influenced the results. The findings concern adults aged 40 or older with type 2 diabetes and established cardiovascular disease, not younger people or those without these conditions.
